Protalix BioTherapeutics (PLX) Tops Q1 EPS by 3c, Revenues Beat

Protalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of ($0.14), $0.03 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $11.32 million versus the consensus estimate of $10.95 million.

"While the receipt of the Complete Response Letter last month from the FDA was disappointing, we are encouraged that the FDA did not report any potential safety or efficacy concerns for PRX-102," said Dror Bashan, Protalix's President and Chief Executive Officer. "We are working closely with the FDA and anticipate the required inspection and subsequent assessment will be completed once the FDA's travel restrictions are lifted. We continue to advance our earlier stage pipeline and anticipate continued progress throughout 2021. We are grateful for the support of our clinicians, patients, shareholders, Board members, employees and external partners and look forward to building stockholder value," concluded Mr. Bashan.

For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• Ennis (EBF) Reports In-Line Q1 EPS
• Reliance Global Group names new CTO, COO, and EVP for AI push